Stockscreener 앱 받기
1.44
0.69%
-0.01
시장 영업 전:
1.44
Zentalis Pharmaceuticals Inc 주식(ZNTL)의 최신 뉴스
How to integrate Zentalis Pharmaceuticals Inc. into portfolio analysis toolsTrade Setup Builder with Custom Alerts - Newser
Analyzing recovery setups for Zentalis Pharmaceuticals Inc. investorsFree Swing Trading Plan With Smart Signals - Newser
Leerink Partnrs Has Pessimistic View of ZNTL Q3 Earnings - Defense World
Can a trend reversal in Zentalis Pharmaceuticals Inc. lead to recoveryFree Fast Return Equity Trade Forecast - Newser
Custom watchlist performance reports with Zentalis Pharmaceuticals Inc.Price Spike Prediction for Active Traders - Newser
Equities Analysts Offer Predictions for ZNTL Q3 Earnings - Defense World
Zentalis Pharmaceuticals Inc. stock outlook for YEARSecure Buy Strategy Based on Risk Parameters - Newser
Applying Wyckoff theory to Zentalis Pharmaceuticals Inc. stockFree Alert Feed for Momentum Based Picks - Newser
When is the best time to exit Zentalis Pharmaceuticals Inc.Predictive AI Signals for Short-Term Trading - Newser
Wall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Hold - Defense World
Why Zentalis Pharmaceuticals Inc. stock attracts strong analyst attentionFree Trend Analysis for Safer Trades - Newser
Using economic indicators to assess Zentalis Pharmaceuticals Inc. potentialInvestment Timeline and ROI Summary Report - Newser
Zentalis price target lowered to $5 from $6 at Wells Fargo - TipRanks
ZNTL: Wells Fargo Adjusts Price Target, Maintains Rating | ZNTL Stock News - GuruFocus
Zentalis Pharmaceuticals: Hold Rating Amid Delayed Catalysts and Market Skepticism - TipRanks
Strategic Advancements and Promising Clinical Data Support Buy Rating for Zentalis Pharmaceuticals - TipRanks
Zentalis Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Sentiment analysis tools applied to Zentalis Pharmaceuticals Inc.Free Growth Focused Entry Plan Suggestions - Newser
Zentalis Pharmaceuticals Reports Improved Financial Results - TipRanks
Zentalis (ZNTL) Q2 Loss Narrows 70% - The Motley Fool
Zentalis (ZNTL) Q2 Loss Narrows 70% - AOL.com
Zentalis Pharmaceuticals: Navigating the Crossroads of Innovation and Financial Prudence - AInvest
Zentalis Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress - GlobeNewswire
Zentalis Advances Revolutionary Ovarian Cancer Drug with $303M War Chest, FDA Fast-Track Potential - Stock Titan
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
51,061 Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Bought by Universal Beteiligungs und Servicegesellschaft mbH - Defense World
Real time social sentiment graph for Zentalis Pharmaceuticals Inc.Free Portfolio Diversification Stock Ideas - Newser
Zentalis Pharmaceuticals Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
When is Zentalis Pharmaceuticals Inc. stock expected to show significant growthSkyrocketing profit margins - Jammu Links News
What is the risk reward ratio of investing in Zentalis Pharmaceuticals Inc. stockHigh-octane financial growth - Jammu Links News
Is Zentalis Pharmaceuticals Inc. stock overvalued or undervaluedDiscover stock picks with superior returns - Jammu Links News
What makes Zentalis Pharmaceuticals Inc. stock price move sharplyGet daily updates on promising stocks - Jammu Links News
Should I hold or sell Zentalis Pharmaceuticals Inc. stock in 2025Stay informed with daily expert analysis - Jammu Links News
What are analysts’ price targets for Zentalis Pharmaceuticals Inc. in the next 12 monthsFree Wealth Management Insights - Jammu Links News
What catalysts could drive Zentalis Pharmaceuticals Inc. stock higher in 2025Maximize returns with data-driven strategies - Jammu Links News
What is the dividend policy of Zentalis Pharmaceuticals Inc. stockExplosive trading opportunities - Jammu Links News
Is Zentalis Pharmaceuticals Inc. a good long term investmentStay ahead with daily expert stock picks - Jammu Links News
What institutional investors are buying Zentalis Pharmaceuticals Inc. stockAchieve breakthrough financial results today - Jammu Links News
0.24%
3.39%
자본화:
|
볼륨(24시간):